Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/26/2003CN1406140A Nano capsule encapsulation system and method
03/26/2003CN1406137A Caspase activated prodrugs therapy
03/26/2003CN1406136A Novel antibody with specificity for colon cancer
03/26/2003CN1405312A Recombinant virus capable of specific killing tumor relating to EB virus and constructing method thereof
03/26/2003CN1405311A Cnidarian cytotoxin gene and its expression and application
03/26/2003CN1405301A Polypeptide-alcohol dehydrogenase III-51.37 and polynucleotide coding said polypeptide
03/26/2003CN1405184A Anti-small cell lung carcinoma polypeptide mixture
03/26/2003CN1405179A Novel antitumor compound Philinopside B from striped pseudo-manatee
03/26/2003CN1405178A Novel anti-tumor compound Intercedenside B from picolour zhuopianshen
03/26/2003CN1405172A Lactosamino fat, preparation method and application thereof
03/26/2003CN1405171A Tega fur-containing lecithin compound and its synthesis
03/26/2003CN1405164A Corter pseudolaricis acid derivatives, preparation method and use thereof
03/26/2003CN1405162A C7 ester-substituted taxane
03/26/2003CN1405152A Anti-tumor 2-amino-carboyl-1,2-di (methylsulfonyl)-1-(substituted) diazane
03/26/2003CN1405144A 由海龙科动物提取的海龙素及其制法和用途 Dragon species extracted by Dragon hormone preparation and use
03/26/2003CN1405139A Triterpenoid, its preparation method and drug composition using the same as active component
03/26/2003CN1405127A Nitrogenous group conversion method
03/26/2003CN1404879A Hormone target chemotherapy medicine for lymph using C as carrier, and use thereof
03/26/2003CN1404876A Use of anti-CTLA anti-body
03/26/2003CN1404841A Novel use of iodine tincture in treating tumor medicine
03/26/2003CN1404833A 药物组合物 The pharmaceutical composition of
03/26/2003CN1404830A Method for preparing controllable complex of taxiol and polylactic acid
03/26/2003CN1404824A Transdermal absorbing composition containing tumor radiotherapy sensitive-increasing agent
03/26/2003CN1103815C Thrombin mutants
03/26/2003CN1103775C Vitronectin receptor antagonists, their preparation and use
03/26/2003CN1103766C Novel taxoids, preparation thereof and pharmaceutical compositions containing same
03/26/2003CN1103755C Novel structural analogues of vitamin D
03/25/2003US6538174 Animal model for transplantation
03/25/2003US6538149 Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
03/25/2003US6538123 Vaccine composition for preventing or treating hepatitis C
03/25/2003US6538103 Anti-angiogenic agents; kringle 1; use treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, arteriosclerotic plaque formation
03/25/2003US6538038 A method of treating a warm-blooded animal having a vascular proliferative disorder, comprising administering, to the animal, an amount of a prodrug of a tubulin binding agent, other than combretastatin A4 disodium phosphate to achieve
03/25/2003US6538037 Inhibiting the hyperproliferation of malignant or neoplastic cells by treating the cells with an antiproliferative amount of 1 alpha ,24(S)-dihydroxyvitamin D2 the cells being cancers of the lung, neck and head, pancreas, endometrium, bladder
03/25/2003US6538036 Method for preventing and treating peripheral neuropathy by administering selegiline
03/25/2003US6538026 A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl
03/25/2003US6538021 Method for producing luteolin and luteolin derivatives
03/25/2003US6538020 Paclitaxel formulation
03/25/2003US6538019 Produce emulsions containing a material that are insoluble or that have low solubility with respect to water and oil in a high concentration, so as to obtain emulsions which can be preserved for a long period of time. More specifically,
03/25/2003US6538009 Pyrazole derivatives as anti-inflammatory/analgesic agents
03/25/2003US6538001 Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
03/25/2003US6537996 Substituted pyridine or pyrimidine derivatives
03/25/2003US6537995 Heterocyclic carboxamides
03/25/2003US6537993 Compounds for enhancing chemotherapy
03/25/2003US6537990 Combined preparations comprising morpholine anthracyclines and anticancer agent
03/25/2003US6537988 Synergistic methods and compositions for treating cancer
03/25/2003US6537984 Contacting a targeted solid tumor cell population with a combination of a vinca alkaloid selected from vinblastine, vincristine, vinorelbine, and a triptolide in combination dosage to reduce the targeted tumor cell population
03/25/2003US6537982 Method of treating prostatic diseases using active vitamin D analogues
03/25/2003US6537981 26,27-Homologated-20-EPI-2-alklidene-19-nor-vitamin D compounds
03/25/2003US6537980 Vitamin D analogues and their pharmaceutical use
03/25/2003US6537966 Follistatin-3
03/25/2003US6537965 Novel parathyroid hormone (PTH) peptide derivatives. In particular, the invention relates to PTH PTH-2 receptor agonist or antagonist properties to the derivatives.
03/25/2003US6537812 Methods for the production of TcRγδ+ T cells
03/25/2003US6537807 Cells designated CD7+CD34-Lin-; use in treatment of genetic and infectious diseases; identification of substances to promote growth, engraftment, and differentiation of stem cells
03/25/2003US6537805 Self-deleting vectors
03/25/2003US6537764 Method of identifying inhibitors of C—C chemokine receptor 3
03/25/2003US6537594 Vaccina virus comprising cytokine and/or tumor associated antigen genes
03/25/2003US6537587 Compositions containing muscle-derived active agents
03/25/2003US6537585 Methods and compositions for treating solid tumors
03/25/2003US6537560 Nucleic acid sequences encoding melanoma antigens recognized by T lymphocytes and protein and peptides encoded by these sequences
03/25/2003US6537551 Anti-tumor agent comprising salmosin as an active ingredient
03/25/2003US6537193 Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
03/25/2003CA2399569A1 Diagnostic markers and drug targets for treatment of cancer
03/25/2003CA2224093C Human vascular endothelial growth factor 2
03/25/2003CA2201723C Colchicine derivatives and the therapeutical use thereof
03/25/2003CA2200480C New use of prostaglandins
03/25/2003CA2107961C Injectable mesna solutions
03/25/2003CA2051239C Prodrugs of phosphonates
03/21/2003WO2002022555A1 Substituted biphenyl derivatives, method for preparing same and pharmaceutical compositions containing same
03/20/2003WO2003023472A1 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths
03/20/2003WO2003023404A1 A method of diagnosis and treatment and agents useful for same
03/20/2003WO2003023398A1 Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor
03/20/2003WO2003023054A1 New assay for inhibitors of translocases
03/20/2003WO2003023048A2 METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
03/20/2003WO2003023045A1 Sulfated polysaccharides, process for producing the same and substances having the same as the active ingredient
03/20/2003WO2003023042A1 Recombinant mva capable of expressing structural hcv antigens
03/20/2003WO2003023031A1 Method of evaluating efficacy of nucleic acid therapy
03/20/2003WO2003023026A1 Alphavirus replicon vector systems
03/20/2003WO2003023014A2 Human ion channels
03/20/2003WO2003023008A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003WO2003023001A2 Novel proteins and nucleic acids encoding same
03/20/2003WO2003022995A2 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003WO2003022883A2 Use of proteins for the production of a medicament for stimulating the innate non specific immune system
03/20/2003WO2003022874A1 Antagonist peptides to vegr receptor flt-1
03/20/2003WO2003022871A2 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
03/20/2003WO2003022852A2 Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
03/20/2003WO2003022846A1 1-glyoxlylamide indolizines for treating cancer
03/20/2003WO2003022844A2 Synthesis of epothilones intermediates thereto and analogues thereof
03/20/2003WO2003022842A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003WO2003022840A1 Pyridine derivatives as raf kinase inhibitors
03/20/2003WO2003022838A1 Pyridine substituted furan derivatives as raf kinase inhibitors
03/20/2003WO2003022837A1 Heterocycle-carboxamide derivatives as raf kinase inhibitors
03/20/2003WO2003022836A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors
03/20/2003WO2003022835A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
03/20/2003WO2003022833A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022832A1 Pyridylfurans and pyrroles as raf kinase inhibitors
03/20/2003WO2003022815A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
03/20/2003WO2003022806A2 Cbi analogues of cc-1065 and the duocarmycins
03/20/2003WO2003022805A2 Heterocycle substituted purines as antiproliferative agents
03/20/2003WO2003022801A1 Reverse hydroxamic acid derivatives
03/20/2003WO2003022787A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
1 ... 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 ... 2211